Book contents
- Frontmatter
- Contents
- Contributors
- Foreword by Sir Gregory Winter
- Preface
- RECOMBINANT ANTIBODIES FOR IMMUNOTHERAPY
- PART I HUMANIZED ANTIBODIES
- PART II GENERATION AND SCREENING OF ANTIBODY LIBRARIES
- PART III TRANSGENIC HUMAN ANTIBODY REPERTOIRES
- 7 Therapeutic Antibodies from XenoMouse Transgenic Mice
- 8 VelocImmune: Immunoglobulin Variable Region Humanized Mice
- PART IV ANTIBODY EFFECTOR FUNCTION
- PART V ARMING ANTIBODIES
- PART VI NOVEL ANTIBODY FORMATS
- PART VII ANTIGEN-BINDING REPERTOIRES OF NON-IMMUNOGLOBULIN PROTEINS
- PART VIII PROLONGATION OF SERUM HALF-LIFE
- PART IX INNOVATIVE IMMUNOTHERAPEUTIC APPROACHES
- PART X MARKET OVERVIEW AND OUTLOOK
- Index
- Plate section
- References
8 - VelocImmune: Immunoglobulin Variable Region Humanized Mice
from PART III - TRANSGENIC HUMAN ANTIBODY REPERTOIRES
Published online by Cambridge University Press: 15 December 2009
Edited by
Book contents
- Frontmatter
- Contents
- Contributors
- Foreword by Sir Gregory Winter
- Preface
- RECOMBINANT ANTIBODIES FOR IMMUNOTHERAPY
- PART I HUMANIZED ANTIBODIES
- PART II GENERATION AND SCREENING OF ANTIBODY LIBRARIES
- PART III TRANSGENIC HUMAN ANTIBODY REPERTOIRES
- 7 Therapeutic Antibodies from XenoMouse Transgenic Mice
- 8 VelocImmune: Immunoglobulin Variable Region Humanized Mice
- PART IV ANTIBODY EFFECTOR FUNCTION
- PART V ARMING ANTIBODIES
- PART VI NOVEL ANTIBODY FORMATS
- PART VII ANTIGEN-BINDING REPERTOIRES OF NON-IMMUNOGLOBULIN PROTEINS
- PART VIII PROLONGATION OF SERUM HALF-LIFE
- PART IX INNOVATIVE IMMUNOTHERAPEUTIC APPROACHES
- PART X MARKET OVERVIEW AND OUTLOOK
- Index
- Plate section
- References
Summary
The study of immunology is inexorably linked to the practice of animal husbandry. For example, the word “vaccinate” is derived from the Latin vaccinus meaning “of or from cows.” The name stems from the practice of protecting people from the deadly smallpox virus by inoculating them with an extract derived from sores of cow udders infected with the innocuous cowpox virus. Later, the serum of animals that had been repeatedly exposed to sublethal doses of diptheria toxin was shown to protect humans against diphtheria, a discovery that eventually led to the discovery of antibodies. Eventually the study of antibody-producing cells in mice led to the invention of monoclonal antibody technology by Kohler and Milstein in 1975. Thus, it is no surprise that germline engineering of the mouse was put to immunological use soon after this powerful technology was developed. Here I describe the VelocImmune® mouse created several years ago by megabase-scale humanization of the variable portion of mouse immunoglobulin (Ig) loci, by far the largest such precision genome-engineering project to date, and compare it with other methods for the generation of humanized or fully human monoclonal antibody therapeutics.
ANTIBODY THERAPEUTICS
Monoclonal antibodies have numerous advantages as drugs. They possess the qualities of (1) high affinity and exquisite specificity leading to few off-target effects and generally superb safety profiles, (2) long half-life leading to infrequent dosing, and (3) reproducible physical characteristics leading to routine production and shortened development time lines.
- Type
- Chapter
- Information
- Recombinant Antibodies for Immunotherapy , pp. 100 - 108Publisher: Cambridge University PressPrint publication year: 2009
References
, Immunotherapy: past, present and future. Nat Med, 2003. 9(3): pp. 269–77.CrossRefGoogle ScholarPubMed
and , Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 1975. 256(5517): pp. 495–7.CrossRefGoogle ScholarPubMed
, et al., A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature, 1991. 350(6317): pp. 423–6.CrossRefGoogle Scholar
, , et al., Humanization of several megabases of mouse immunoglobulin variable gene loci. Manuscript in preparation.
, , et al., Mouse immunoglobulin gene loci with megabase humanization of only the variable region function with as efficiently as normal mouse immunoglobulin loci. Manuscript in preparation.
, et al., Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA, 1984. 81(21): pp. 6851–5.CrossRefGoogle ScholarPubMed
, , and , Production of functional chimaeric mouse/human antibody. Nature, 1984. 312(5995): pp. 643–6.CrossRefGoogle ScholarPubMed
, et al., Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet, 1994. 344(8930): pp. 1105–10.CrossRefGoogle ScholarPubMed
and , Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: the EPIC Trial results. J Invasive Cardiol, 1994. 6 Suppl A: pp. 19A–28A; discussion 45A–50A.Google ScholarPubMed
, et al., Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet, 1997. 350(9086): pp. 1193–8.CrossRefGoogle ScholarPubMed
, et al., IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood, 1997. 90(6): pp. 2188–95.Google ScholarPubMed
, et al., Phage antibodies: filamentous phage displaying antibody variable domains. Nature, 1990. 348(6301): pp. 552–4.CrossRefGoogle ScholarPubMed
and , Adalimumab – a new TNF-alpha antibody for treatment of inflammatory joint disease. Expert Opin Biol Ther, 2003. 3(2): pp. 351–60.Google ScholarPubMed
, et al., A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA, 1989. 86(24): pp. 10029–33.CrossRefGoogle ScholarPubMed
, et al., Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA, 1992. 89(10): pp. 4285–9.CrossRefGoogle ScholarPubMed
, et al., Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature, 1994. 368(6474): pp. 856–9.CrossRefGoogle ScholarPubMed
, et al., Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat Genet, 1994. 7(1): pp. 13–21.CrossRefGoogle ScholarPubMed
, et al., Double trans-chromosomic mice: maintenance of two individual human chromosome fragments containing Ig heavy and kappa loci and expression of fully human antibodies. Proc Natl Acad Sci USA, 2000. 97(2): pp. 722–7.CrossRefGoogle ScholarPubMed
, et al., Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature, 2008. 453(7195): pp. 667–71.CrossRefGoogle ScholarPubMed
., Human antibodies from transgenic animals. Nat Biotechnol, 2005. 23(9): pp. 1117–25.CrossRefGoogle ScholarPubMed
, et al., High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat Biotechnol, 1996. 14(7): pp. 845–51.CrossRefGoogle ScholarPubMed
, et al., Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat Genet, 1997. 15(2): pp. 146–56.CrossRefGoogle ScholarPubMed
, et al., FDA drug approval summary: panitumumab (Vectibix). Oncologist, 2007. 12(5): pp. 577–83.CrossRefGoogle Scholar
, et al., Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet, 2008. 371(9625): pp. 1665–74.CrossRefGoogle Scholar
, et al., Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial. Bone, 2008. 43(2): pp. 222–29.CrossRefGoogle Scholar
, et al., First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood, 2008. 111(12): pp. 5486–95.CrossRefGoogle ScholarPubMed
, et al., Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum, 2008. 58(4): pp. 964–75.CrossRefGoogle ScholarPubMed
, et al., High-throughput engineering of the mouse genome coupled with high-resolution expression analysis. Nat Biotechnol, 2003. 21(6): pp. 652–9.CrossRefGoogle ScholarPubMed
, et al., F0 generation mice fully derived from gene-targeted embryonic stem cells allowing immediate phenotypic analyses. Nat Biotechnol, 2007. 25(1): pp. 91–9.CrossRefGoogle ScholarPubMed
., Production and selection of antigen-specific fully human monoclonal antibodies from mice engineered with human Ig loci. Adv Drug Deliv Rev, 1998. 31(1–2): pp. 33–42.CrossRefGoogle ScholarPubMed
- 2
- Cited by